Literature DB >> 20142361

Mechanism of T cell tolerance induced by myeloid-derived suppressor cells.

Srinivas Nagaraj1, Adam G Schrum, Hyun-Il Cho, Esteban Celis, Dmitry I Gabrilovich.   

Abstract

Ag-specific T cell tolerance plays a critical role in tumor escape. Recent studies implicated myeloid-derived suppressor cells (MDSCs) in the induction of CD8(+) T cell tolerance in tumor-bearing hosts. However, the mechanism of this phenomenon remained unclear. We have found that incubation of Ag-specific CD8(+) T cells, with peptide-loaded MDSCs, did not induce signaling downstream of TCR. However, it prevented subsequent signaling from peptide-loaded dendritic cells. Using double TCR transgenic CD8(+) T cells, we have demonstrated that MDSC induced tolerance to only the peptide, which was presented by MDSCs. T cell response to the peptide specific to the other TCR was not affected. Incubation of MDSCs with Ag-specific CD8(+) T cells caused nitration of the molecules on the surface of CD8(+) T cells, localized to the site of physical interaction between MDSC and T cells, which involves preferentially only TCR specific for the peptide presented by MDSCs. Postincubation with MDSCs, only nitrotyrosine-positive CD8(+) T cells demonstrated profound nonresponsiveness to the specific peptide, whereas nitrotyrosine-negative CD8(+) T cells responded normally to that stimulation. MDSCs caused dissociation between TCR and CD3zeta molecules, disrupting TCR complexes on T cells. Thus, these data describe a novel mechanism of Ag-specific CD8(+) T cell tolerance in cancer.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20142361      PMCID: PMC2832724          DOI: 10.4049/jimmunol.0902661

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  38 in total

1.  LacZ inducible, antigen/MHC-specific T cell hybrids.

Authors:  S Sanderson; N Shastri
Journal:  Int Immunol       Date:  1994-03       Impact factor: 4.823

2.  Partial degradation of T-cell signal transduction molecules by contaminating granulocytes during protein extraction of splenic T cells from tumor-bearing mice.

Authors:  J L Franco; P Ghosh; R H Wiltrout; C R Carter; A H Zea; N Momozaki; A C Ochoa; D L Longo; T J Sayers; K L Komschlies
Journal:  Cancer Res       Date:  1995-09-01       Impact factor: 12.701

3.  Inhibition of myeloid cell differentiation in cancer: the role of reactive oxygen species.

Authors:  Sergei Kusmartsev; Dmitry I Gabrilovich
Journal:  J Leukoc Biol       Date:  2003-08       Impact factor: 4.962

Review 4.  TCR zeta-chain downregulation: curtailing an excessive inflammatory immune response.

Authors:  Michal Baniyash
Journal:  Nat Rev Immunol       Date:  2004-09       Impact factor: 53.106

5.  Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice.

Authors:  H Mizoguchi; J J O'Shea; D L Longo; C M Loeffler; D W McVicar; A C Ochoa
Journal:  Science       Date:  1992-12-11       Impact factor: 47.728

6.  Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species.

Authors:  Sergei Kusmartsev; Yulia Nefedova; Daniel Yoder; Dmitry I Gabrilovich
Journal:  J Immunol       Date:  2004-01-15       Impact factor: 5.422

7.  Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens.

Authors:  A Y Huang; P Golumbek; M Ahmadzadeh; E Jaffee; D Pardoll; H Levitsky
Journal:  Science       Date:  1994-05-13       Impact factor: 47.728

8.  Activated macrophages induce structural abnormalities of the T cell receptor-CD3 complex.

Authors:  T Aoe; Y Okamoto; T Saito
Journal:  J Exp Med       Date:  1995-05-01       Impact factor: 14.307

9.  T cells from late tumor-bearing mice express normal levels of p56lck, p59fyn, ZAP-70, and CD3 zeta despite suppressed cytolytic activity.

Authors:  D L Levey; P K Srivastava
Journal:  J Exp Med       Date:  1995-10-01       Impact factor: 14.307

10.  Do structural changes of T cell receptor complex occur in tumor-bearing state?

Authors:  S Noda; T Nagata-Narumiya; A Kosugi; S Narumiya; C Ra; H Fujiwara; T Hamaoka
Journal:  Jpn J Cancer Res       Date:  1995-04
View more
  170 in total

1.  Novel and enhanced anti-melanoma DNA vaccine targeting the tyrosinase protein inhibits myeloid-derived suppressor cells and tumor growth in a syngeneic prophylactic and therapeutic murine model.

Authors:  J Yan; C Tingey; R Lyde; T C Gorham; D K Choo; A Muthumani; D Myles; L P Weiner; K A Kraynyak; E L Reuschel; T H Finkel; J J Kim; N Y Sardesai; K E Ugen; K Muthumani; D B Weiner
Journal:  Cancer Gene Ther       Date:  2014-11-14       Impact factor: 5.987

Review 2.  Inhibiting the inhibitors: evaluating agents targeting cancer immunosuppression.

Authors:  Theresa L Whiteside
Journal:  Expert Opin Biol Ther       Date:  2010-07       Impact factor: 4.388

Review 3.  Immune Evasion by Head and Neck Cancer: Foundations for Combination Therapy.

Authors:  Joshua D Horton; Hannah M Knochelmann; Terry A Day; Chrystal M Paulos; David M Neskey
Journal:  Trends Cancer       Date:  2019-03-20

4.  In vivo suppressive function of myeloid-derived suppressor cells is limited to the inflammatory site.

Authors:  Jessica M Haverkamp; Scott A Crist; Bennett D Elzey; Cansu Cimen; Timothy L Ratliff
Journal:  Eur J Immunol       Date:  2011-02-02       Impact factor: 5.532

5.  Development of tumor-infiltrating CD8+ T cell memory precursor effector cells and antimelanoma memory responses are the result of vaccination and TGF-β blockade during the perioperative period of tumor resection.

Authors:  Emily C Bellavance; Frederick J Kohlhapp; Andrew Zloza; Jeremy A O'Sullivan; James McCracken; Michael C Jagoda; Andrew T Lacek; Mitchell C Posner; Jose A Guevara-Patino
Journal:  J Immunol       Date:  2011-02-02       Impact factor: 5.422

Review 6.  Regulation of suppressive function of myeloid-derived suppressor cells by CD4+ T cells.

Authors:  Srinivas Nagaraj; Dmitry I Gabrilovich
Journal:  Semin Cancer Biol       Date:  2012-01-31       Impact factor: 15.707

Review 7.  Cross-talk between myeloid-derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumor-induced immune suppression.

Authors:  Suzanne Ostrand-Rosenberg; Pratima Sinha; Daniel W Beury; Virginia K Clements
Journal:  Semin Cancer Biol       Date:  2012-02-01       Impact factor: 15.707

8.  Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans.

Authors:  Güllü Topal Görgün; Gregory Whitehill; Jennifer L Anderson; Teru Hideshima; Craig Maguire; Jacob Laubach; Noopur Raje; Nikhil C Munshi; Paul G Richardson; Kenneth C Anderson
Journal:  Blood       Date:  2013-01-15       Impact factor: 22.113

9.  Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival.

Authors:  Steffen Walter; Toni Weinschenk; Arnulf Stenzl; Romuald Zdrojowy; Anna Pluzanska; Cezary Szczylik; Michael Staehler; Wolfram Brugger; Pierre-Yves Dietrich; Regina Mendrzyk; Norbert Hilf; Oliver Schoor; Jens Fritsche; Andrea Mahr; Dominik Maurer; Verona Vass; Claudia Trautwein; Peter Lewandrowski; Christian Flohr; Heike Pohla; Janusz J Stanczak; Vincenzo Bronte; Susanna Mandruzzato; Tilo Biedermann; Graham Pawelec; Evelyna Derhovanessian; Hisakazu Yamagishi; Tsuneharu Miki; Fumiya Hongo; Natsuki Takaha; Kosei Hirakawa; Hiroaki Tanaka; Stefan Stevanovic; Jürgen Frisch; Andrea Mayer-Mokler; Alexandra Kirner; Hans-Georg Rammensee; Carsten Reinhardt; Harpreet Singh-Jasuja
Journal:  Nat Med       Date:  2012-07-29       Impact factor: 53.440

10.  Changes in peripheral blood immune cells: their prognostic significance in metastatic renal cell carcinoma patients treated with molecular targeted therapy.

Authors:  Minoru Kobayashi; Taro Kubo; Kenji Komatsu; Akira Fujisaki; Fumihito Terauchi; Shinsuke Natsui; Akinori Nukui; Shinsuke Kurokawa; Tatsuo Morita
Journal:  Med Oncol       Date:  2013-03-29       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.